Evidence map›Paper›PMID 25915630›Full record

ArticlePloS one2015

Enhanced Sensitivity for Detection of HIV-1 p24 Antigen by a Novel Nuclease-Linked Fluorescence Oligonucleotide Assay.

Peihu Fan, Xiaojun Li, Weiheng Su, Wei Kong, Xianggui Kong, Zhenxin Wang, Youchun Wang, Chunlai Jiang, Feng Gao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. The principles and applications of avidin-based nanoparticles in drug delivery and diagnosis.Journal of controlled release : official journal of the Controlled Release Society · 2017
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Peihu FanSchool of Life Sciences, Jilin University, Changchun, Jilin, China; National Engineering Laboratory for Acquired Immune Deficiency Syndrome Vaccine, Jilin University, Changchun, Jilin, China.
Xiaojun LiSchool of Life Sciences, Jilin University, Changchun, Jilin, China; National Engineering Laboratory for Acquired Immune Deficiency Syndrome Vaccine, Jilin University, Changchun, Jilin, China.
Weiheng SuSchool of Life Sciences, Jilin University, Changchun, Jilin, China; National Engineering Laboratory for Acquired Immune Deficiency Syndrome Vaccine, Jilin University, Changchun, Jilin, China.
Wei KongSchool of Life Sciences, Jilin University, Changchun, Jilin, China; National Engineering Laboratory for Acquired Immune Deficiency Syndrome Vaccine, Jilin University, Changchun, Jilin, China; Key Laboratory for Molecular Enzymology & Engineering, Jilin University, Changchun, Jilin, China.
Xianggui KongState Key Laboratory of Luminescence and Applications, Changchun Institute of Optics, Fine Mechanics and Physics, Chinese Academy of Sciences, Changchun, Jilin, China.
Zhenxin WangState Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, China.
Youchun WangDivision of Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome and Sex-transmitted Virus Vaccines, National Institutes for Food and Drug Control, Beijing, China.
Chunlai JiangSchool of Life Sciences, Jilin University, Changchun, Jilin, China; National Engineering Laboratory for Acquired Immune Deficiency Syndrome Vaccine, Jilin University, Changchun, Jilin, China; Key Laboratory for Molecular Enzymology & Engineering, Jilin University, Changchun, Jilin, China.
Feng GaoSchool of Life Sciences, Jilin University, Changchun, Jilin, China; National Engineering Laboratory for Acquired Immune Deficiency Syndrome Vaccine, Jilin University, Changchun, Jilin, China.
Jilin University · CNChangchun Institute of Applied Chemistry · CNChinese Academy of Sciences · CNNational Institutes for Food and Drug Control · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The relatively high detection limit of the Enzyme-linked immunosorbent assay (ELISA) prevents its application for detection of low concentrations of antigens. To increase the sensitivity for detection of HIV-1 p24 antigen, we developed a highly sensitive nuclease-linked fluorescence oligonucleotide assay (NLFOA). Two major improvements were incorporated in NLFOA to amplify antibody-antigen interaction signals and reduce the signal/noise ratio; a large number of nuclease molecules coupled to the gold nanoparticle/streptavidin complex and fluorescent signals generated from fluorescent-labeled oligonucleotides by the nuclease. The detection limit of p24 by NLFOA was 1 pg/mL, which was 10-fold more sensitive than the conventional ELISA (10 pg/mL). The specificity was 100% and the coefficient of variation (CV) was 7.8% at low p24 concentration (1.5 pg/mL) with various concentrations of spiked p24 in HIV-1 negative sera. Thus, NLFOA is highly sensitive, specific, reproducible and user-friendly. The more sensitive detection of low p24 concentrations in HIV-1-infected individuals by NLFOA could allow detection of HIV-1 infections that are missed by the conventional ELISA at the window period during acute infection to further reduce the risk for HIV-1 infection due to the undetected HIV-1 in the blood products. Moreover, NLFOA can be easily applied to more sensitive detection of other antigens.

Indexed as

Fluorescent DyesFluoroimmunoassayHIV AntibodiesHIV Core Protein p24HIV InfectionsHumansNanoconjugatesOligonucleotidesRibonucleasesSensitivity and SpecificityFluorescent DyesHIV AntibodiesHIV Core Protein p24NanoconjugatesOligonucleotidesRibonucleases

Identifiers

PMID25915630
PMCPMC4410951
OpenAlexW2045573882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.